http://orcid.org/0000-0001-9408-5882
References
- Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014;5:197.
- Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma. 2005;46:49–54.
- Travis LB, Curtis RE, Hankey BF, et al. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992;84:1422–1427.
- Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002;20:3878–3884.
- Park TS, Cheong JW, Song J, et al. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia. Leuk Res. 2009;33:1001–1004.
- Payandeh M, Sadeghi E, Khodarahmi R, et al. Appearance and disappearance of chronic myeloid leukemia (CML) in patient with chronic lymphocytic leukemia (CLL). Int J Hematol Oncol Stem Cell Res. 2014;8:49–53.
- Hattori H, Kuwayama M, Kotake T, et al. [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia]. Gan to Kagaku Ryoho. 2011;38:333–336
- Rahman K, George S, Mangal S, et al. Simultaneous occurrence of chronic myeloid leukemia and chronic lymphocytic leukemia: report of an unusual case. Indian J Pathol Microbiol. 2013;56:453–456.
- Katovic SK, Vasilj A, Maricevic L, et al. Simultaneous occurrence of chronic lymphocytic and chronic myeloid leukemia. Coll Antropol. 2010;34:653–655.
- Esteve J, Cervantes F, Rives S, et al. Simultaneous occurrence of B-cell chronic lymphocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid blast crisis. Haematologica. 1997;82:596–599.
- Nagao T, Takahashi N, Kameoka Y, et al. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. Intern Med. 2013;52:2567–2571.
- Chang H, Sutherland R, Nayar R, et al. Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting. Cancer Genet Cytogenet. 2004;152:146–148.
- Emilia G, Marasca R, Zucchini P, et al. BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood. 2001;97:2187–2189.
- Jurdi A, Krishnan K, Chakraborty K. A 'double-hit' bone marrow rare co-occurrence of 2 different pathologies. J Community Support Oncol. 2014;12:33–34.
- Campregher PV, Hamerschlak N. Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice. Clin Lymphoma Myeloma Leuk. 2014;14:271–276.
- D'Arena G, Gemei M, Lucialno L, et al. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? J Clin Oncol. 2012;30:e327–e330.
- Bao F, Munker R, Lowery C, et al. Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther. 2007;11:239–245.
- Fink AM, Bahlo J, Robrecht S, et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017;4:e475–e486.
- Filppula AM, Laitila J, Neuvonen PJ, et al. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012;165:2787–2798.
- Shea LK, Mikhail FM, Forero-Torres A, et al. Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia. Clin Case Rep. 2017;5:899–901.
- Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055–4063.
- Amrein PC. The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Leuk Lymphoma. 2011;52:754–763.